KKR Asian Fund IV SCSp managed by KKR & Co. Inc. (NYSE:KKR) made an offer to acquire 26% stake in HealthCare Global Enterprises Limited (NSEI:HCG) for INR 18.7 billion on February 23, 2025. A cash consideration valued at INR 504.41 per share will be paid by KKR Asian Fund IV SCSp. As part of consideration, INR 18.7 billion is paid towards common equity of HealthCare Global Enterprises Limited. The transaction has been approved by Competition Commission of India and is still subject to approval by Competition Authority of Kenya. The deal is also subject to statutory approvals. The deal is expected to be completed on May 7, 2025. As of July The recommendation of the IDC was approved on July 12, 2025 and published on July 14, 2025 in the Newspapers in which the Detailed Public Statement was published the offer is fair and reasonable.

Ganesh Rane of Kotak Mahindra Capital Company Limited acted as financial advisor and M Murali Krishna of KFin Technologies Limited (NSEI:KFINTECH) acted as registrar to KKR & Co. Inc.

As per revised schedule, the deal is expected to be completed on August 01, 2025.